Product Code: GVR-1-68038-869-5
Platelet Rich Plasma Market Growth & Trends
The global platelet rich plasma market size is estimated to reach USD 1.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.0% from 2021 to 2028. Several research studies have been performed recently to assess the conditions and incidences of platelet rich plasma (PRP) usage across both nonoperative as well as operative settings. Recent research on these lines has concluded that the breadth and use of platelet rich plasma have increased significantly among Medicare beneficiaries, which is expected to drive the market.
Technological advancements in the development of novel and innovative platelet rich plasma products are expected to propel market growth. Market participants are developing advanced products to reinforce their market share and overcome current limitations. In February 2020, Florida-based EmCyte Corporation received FDA's 510(k) approval for its PurePRP Supraphysiologic Concentrating System, intended for producing platelet rich plasma from a small quantity of blood sample at Point-of-care (PoC) settings. This is an advanced autologous biologic concentrating system that can enable clinicians to improve their work.
The potential value of the market products lies in its ability to include high concentrations of platelet-derived fibrin and growth factors. Several research studies have demonstrated beneficial results with the usage of PRP in a wide range of clinical applications, such as orthopedics, sports medicine, cosmetic surgery, general surgery, neurosurgery, ophthalmic surgery, and others.
PRP injections are widely accepted in the orthopedic treatment, particularly focused towards joint pain relief and other bone defects, propelling the industry growth. It is also used to stimulate the formation of bone in spinal fusion surgeries. Additionally, integration of PRP in the management of COVID-19 patients, as an adjunct therapy is further expected to offer profitable business opportunities for the entities operational in this market.
Platelet Rich Plasma Market Report Highlights
- The pure PRP segment accounted for the largest revenue share of over 52.0% in 2020. Compared to Leukocyte Rich Platelet rich plasma (LR-PRP), pure PRP can promote better repair of bone defects
- LR-PRP can enhance bone regeneration by improving viability, proliferation, migration of cells in vitro, and osteogenesis and angiogenesis in vitro and in vivo
- However, LR-PRP products can produce adverse or inferior effects, making pure type more suitable for bone regeneration
- The combined use of P-PRP with B-tricalcium phosphate (B-TCP) is considered a simple, safe, and effective option in the treatment of bone defects. These factors are expected to boost the utilization of the same
- Orthopedics dominated the market in 2020 accounting for a market share of more than 29.0%, while dermatology is expected to witness the fastest growth rate over the forecast period
- A large number of orthopedic and general surgeries being performed in hospitals is contributing to the dominant share held by hospitals in the market
- The growing competition in the global market can be attributed to the presence of several well-established companies as well as small and midsized entities
- Established manufacturers are observing strategic product developments to ensure maximum product reach
- In October 2019, a new design for packaging was introduced by Croma-Pharma GmbH for the company's ACP double syringe system. The unique appearance of Croma products has been integrated in this new design. Croma is an exclusive distributor of the Arthrex ACP double syringe system in 9 countries in Europe
Table of Contents
Chapter 1 Methodology And Scope
- 1.1 Research Methodology
- 1.2 Research Assumptions
- 1.2.1 Estimates and Forecast Timeline
- 1.3 Research Methodology
- 1.4 Information Procurement
- 1.4.1 Purchased Database
- 1.4.2 GVR's Internal Database
- 1.4.3 Secondary Sources
- 1.4.4 Primary Research
- 1.4.5 Details of Primary Research
- 1.5 Information or Data Analysis
- 1.5.1 Platelet Rich Plasma (PRP) Market: segment revenue and growth analysis
- 1.5.2 sports medicine market: segment revenue and growth analysis
- 1.5.3 Platelet Rich Plasma (PRP)-based ulcer healing Market: segment revenue and growth analysis
- 1.5.3.1 Platelet Rich Plasma (PRP)-based ulcer healing Market: segment definition
- 1.5.3.1.1 Non-Healing Ulcers
- 1.5.3.1.1.1 Diabetic Ulcers
- 1.5.3.1.1.2 Pressure Ulcers
- 1.5.3.1.1.3 Pyoderma gangrenosum
- 1.5.3.1.1.4 Venous ulcers
- 1.5.4 Data Analysis Models
- 1.6 Market Formulation & Validation
- 1.7 Model Details
- 1.7.1 Commodity Flow Analysis
- 1.7.1.1 Approach 1: Commodity Flow Approach
- 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.8 Market: CAGR Calculation
- 1.9 List of Secondary Sources
- 1.10 List of Primary Sources
- 1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
Chapter 2 Executive Summary
- 2.1 Competition Milieu
- 2.2 Segment Outlook
- 2.3 Market Summary, 2020 (USD Million)
Chapter 3 Platelet Rich Plasma (PRP) Market Variables, Trends & Scope
- 3.1 Market Segmentation
- 3.2 Parent Market Lineage
- 3.3 Market Dynamics
- 3.3.1 Market Drivers Analysis
- 3.3.1.1 Rise in the incidence of orthopedic disorders and sports injuries
- 3.3.1.2 Increasing number of cosmetic surgery procedures
- 3.3.1.3 Extending medical applications of platelet rich plasma
- 3.3.1.4 Increasing number of evidence-based studies for PRP-based wound healing
- 3.3.2 Market restraint Analysis
- 3.3.2.1 High costs associated with PRP products
- 3.3.3 Market opportunity Analysis
- 3.3.3.1 Increase in the breadth and use of PRP therapy across Medicare beneficiaries
- 3.4 Penetration & Growth Prospect Mapping, by Application, 2020
- 3.5 COVID-19 Impact Analysis: Platelet Rich Plasma (PRP) Market
Chapter 4 Business Environment Analysis
- 4.1 SWOT Analysis; by Factor (Political & Legal, Economic and Technological)
- 4.2 Porter's Five Forces Analysis
Chapter 5 Type Business Analysis
- 5.1 Platelet Rich Plasma (PRP) Market: Type Movement Analysis
- 5.2 Pure PRP
- 5.2.1 Pure PRP market estimates and forecast, 2017 - 2028 (USD Million)
- 5.3 Leukocyte Rich PRP
- 5.3.1 Leukocyte rich PRP market estimates and forecast, 2017 - 2028 (USD Million)
- 5.4 Others
- 5.4.1 PRP market estimates and forecast for others, 2017 - 2028 (USD Million)
Chapter 6 Application Business Analysis
- 6.1 Platelet Rich Plasma (PRP) Market: Application Movement Analysis
- 6.2 Orthopedics
- 6.2.1 Platelet Rich Plasma (PRP) market estimates and forecast for Orthopedics, 2017 - 2028
- 6.3 Sports Medicine
- 6.3.1 Platelet Rich Plasma (PRP) market estimates and forecast for Sports medicine, 2017 - 2028
- 6.4 Cosmetic Surgery
- 6.4.1 Platelet Rich Plasma (PRP) Market estimates and forecast for cosmetic surgery, 2017 - 2028
- 6.5 Dermatology
- 6.5.1 coverage scneario: U.S. Centers for Medicare & Medicaid Services
- 6.5.2 Platelet Rich Plasma (PRP) Market estimates and forecast for dermatology, 2017 - 2028
- 6.5.3 Ulcer healing
- 6.5.3.1 Platelet Rich Plasma (PRP) Market estimates and forecast for ulcer healing, 2017 - 2028
- 6.5.3.2 Venous ulcers
- 6.5.3.2.1 Platelet Rich Plasma (PRP) Market estimates and forecast for venous ulcers, 2017 - 2028
- 6.5.3.3 Traumatic ulcers
- 6.5.3.3.1 Platelet Rich Plasma (PRP) Market estimates and forecast for traumatic ulcers, 2017 - 2028
- 6.5.3.4 Pyoderma gangrenosum ulcers
- 6.5.3.4.1 Platelet Rich Plasma (PRP) Market estimates and forecast for pyoderma gangrenosum ulcers, 2017 - 2028
- 6.5.3.5 Diabetic ulcers
- 6.5.3.5.1 Platelet Rich Plasma (PRP) Market estimates and forecast for diabetic ulcers, 2017 - 2028
- 6.5.3.6 Trophic ulcers
- 6.5.3.6.1 Platelet Rich Plasma (PRP) Market estimates and forecast for trophic ulcers, 2017 - 2028
- 6.5.3.7 Vasculitic ulcers
- 6.5.3.7.1 Platelet Rich Plasma (PRP) Market estimates and forecast for vasculitic ulcers, 2017 - 2028
- 6.5.4 Others
- 6.5.4.1 Platelet Rich Plasma (PRP) Market estimates and forecast for others, 2017 - 2028
- 6.6 Ophthalmic Surgery
- 6.6.1 Platelet Rich Plasma (PRP) market estimates and forecast for Ophthalmic surgery, 2017 - 2028
- 6.7 Neurosurgery
- 6.7.1 Platelet Rich Plasma (PRP) market estimates and forecast for Neurosurgery, 2017 - 2028
- 6.8 General Surgery
- 6.8.1 Platelet Rich Plasma (PRP) market estimates and forecast for General surgery, 2017 - 2028
- 6.9 Others
- 6.9.1 Platelet Rich Plasma (PRP) market estimates and forecast for Others, 2017 - 2028
Chapter 7 End-Use Business Analysis
- 7.1 Platelet Rich Plasma (PRP) Market: End-use Movement Analysis
- 7.2 Hospitals
- 7.2.1 Platelet Rich Plasma (PRP) market for hospitals, 2017 - 2028 (USD Million)
- 7.3 Clinics
- 7.3.1 Platelet Rich Plasma (PRP) market for clinics, 2017 - 2028 (USD Million)
- 7.4 Others
- 7.4.1 Platelet Rich Plasma (PRP) market for others, 2017 - 2028 (USD Million)
Chapter 8 Regional Business Analysis
- 8.1 Platelet Rich Plasma (PRP) Market: Regional Movement Analysis
- 8.2 North America
- 8.2.1 North America Platelet rich plasma (PRP) market estimates and forecast, 2017 - 2028 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 U.S. Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.2.2.2 U.S. Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.2.2.3 U.S. Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.2.3 Canada
- 8.2.3.1 Canada Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.2.3.2 Canada Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.2.3.3 Canada Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.3 Europe
- 8.3.1 Europe Platelet rich plasma (PRP) market estimates and forecast, 2017 - 2028 (USD Million)
- 8.3.2 Germany
- 8.3.2.1 Germany Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.3.2.2 Germany Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.3.2.3 Germany Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.3.3 U.K.
- 8.3.3.1 U.K. Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.3.3.2 U.K. Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.3.3.3 U.K. Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Platelet rich plasma (PRP) market estimates and forecast, 2017 - 2028 (USD Million)
- 8.4.2 Japan
- 8.4.2.1 Japan Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.4.2.2 Japan Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.4.2.3 Japan Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.4.3 China
- 8.4.3.1 China Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.4.3.2 China Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.4.3.3 China Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.5 Latin America
- 8.5.1 Latin America Platelet rich plasma (PRP) market estimates and forecast, 2017 - 2028 (USD Million)
- 8.5.2 Brazil
- 8.5.2.1 Brazil Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.5.2.2 Brazil Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.5.2.3 Brazil Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.5.3 Mexico
- 8.5.3.1 Mexico Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.5.3.2 Mexico Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.5.3.3 Mexico Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
- 8.6 Middle East & Africa
- 8.6.1 Middle East & Africa Platelet rich plasma (PRP) market estimates and forecast, 2017 - 2028 (USD Million)
- 8.6.2 South Africa
- 8.6.2.1 South Africa Platelet rich plasma (PRP) market estimates and forecast, by type, 2017 - 2028 (USD Million)
- 8.6.2.2 South Africa Platelet rich plasma (PRP) market estimates and forecast, by application, 2017 - 2028 (USD Million)
- 8.6.2.3 South Africa Platelet rich plasma (PRP) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
Chapter 9 Company Profile
- 9.1 Strategy Framework
- 9.2 Market Participation Categorization
- 9.3 Company Profiles
- 9.3.1 Johnson & Johnson
- 9.3.1.1 Company overview
- 9.3.1.2 DePuy Synthes
- 9.3.1.2.1 Company overview
- 9.3.1.3 Financial Performance
- 9.3.1.4 Product benchmarking
- 9.3.1.5 Strategic initiatives
- 9.3.2 Arthrex, Inc.
- 9.3.2.1 Company overview
- 9.3.2.2 FINANCIAL PERFORMANCE
- 9.3.2.3 Product benchmarking
- 9.3.2.4 Strategic initiatives
- 9.3.3 EmCyte Corporation
- 9.3.3.1 Company overview
- 9.3.3.2 Product benchmarking
- 9.3.3.3 Strategic initiatives
- 9.3.4 DR. PRP AMERICA, LLC
- 9.3.4.1 Company overview
- 9.3.4.2 Product benchmarking
- 9.3.5 Juventix
- 9.3.5.1 Company overview
- 9.3.5.2 FINANCIAL PERFORMANCE
- 9.3.5.3 Product benchmarking
- 9.3.6 Terumo Corporation
- 9.3.6.1 Company overview
- 9.3.6.2 TERUMO BCT, INC.
- 9.3.6.2.1 Company overview
- 9.3.6.3 Financial Performance
- 9.3.6.4 Product benchmarking
- 9.3.6.5 Strategic initiatives
- 9.3.7 Zimmer Biomet
- 9.3.7.1 Company overview
- 9.3.7.2 Financial Performance
- 9.3.7.3 Product benchmarking
- 9.3.7.4 Strategic initiatives
- 9.3.8 Stryker
- 9.3.8.1 Company overview
- 9.3.8.2 Financial Performance
- 9.3.8.3 Product benchmarking
- 9.3.8.4 Strategic initiatives
- 9.3.9 Apex Biologix
- 9.3.9.1 Company overview
- 9.3.9.2 Financial Performance
- 9.3.9.3 Product benchmarking
- 9.3.9.4 Strategic initiatives
- 9.3.10 Celling Biosciences
- 9.3.10.1 Company overview
- 9.3.10.2 Financial Performance
- 9.3.10.3 Product benchmarking
- 9.3.10.4 Strategic initiatives